Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal

Investigators Highlight Promising T-Cell Response

 
• By Andrew McConaghie

Oxford’s long-awaited early stage study produces solid safety and efficacy results, but lags Pfizer/BioNTech and Moderna’s mRNA candidates for antibody response.

Old Road Campus
Oxford is racing ahead in its Phase III trials, having dosed nearly all its target of 10,000 volunteers.

More from Business

More from Scrip